PLX Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -2301.55%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 528.57%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 41.29%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.248, which suggesting that the stock is 124.798% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 25.18x while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.23x versus 52.01x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -12425.36%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 528.57%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 331.85%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Perspective Therapeutics, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.248, which suggesting that the stock is 124.798% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 25.18x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.23x versus 184.77x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of 12.65%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Electromed, Inc.'s return on equity of 18.89%.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 528.57%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 31.63%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Electromed, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.248, which suggesting that the stock is 124.798% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than Electromed, Inc.'s net income of $2.1M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 25.18x while Electromed, Inc.'s PE ratio is 29.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.23x versus 3.65x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PAVmed, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -120220%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat PAVmed, Inc.'s return on equity of 8.75%.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 528.57%. On the other hand PAVmed, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 3064.56%. Given that PAVmed, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe PAVmed, Inc. is more attractive than Protalix Biotherapeutics, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.248, which suggesting that the stock is 124.798% less volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.095, suggesting its more volatile than the S&P 500 by 9.503%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than PAVmed, Inc. quarterly revenues of $5K. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than PAVmed, Inc.'s net income of -$6M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 25.18x while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.23x versus 267.42x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.